All In Biotech

Drug Trial Radar · NCT03376529

Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741

A Single-center, Multi-arm, Open-label, Randomized, 3-period, Crossover, Phase 1 Study to Evaluate the DDI, PK, Safety, and Tolerability of Single Doses of SPR741 Co-administered With Three Different Antibiotics in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Jan 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Nov 10, 2017

Primary completion

Dec 19, 2017

Study completion Dec 20, 2017

Sponsor

Lead sponsor
Spero TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Simbec Research; QPS Holdings LLC
First posted
Dec 18, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, single-center, multi-arm, open-label, randomized, three-period, crossover study to evaluate the drug-drug interaction, pharmacokinetics, safety, and tolerability of a single dose of SPR741 combined with each of 3 different partner antibiotics (ceftazidime or piperacillin/tazobactam or aztreonam) in healthy volunteers. Participants will be administered single doses of SPR741 alone, a single dose of SPR741 in combination with 1 of 3 different partner antibiotics, and the partner antibiotic alone in a randomized sequence. Twenty-seven (27) adult male and female normal healthy participants 18 to 55 years of age are planned to participate in the study. Women of childbearing potential will not be eligible to participate.

Conditions

  • Healthy Volunteers

Interventions

  • SPR741Drug

    400 mg IV over 1 hour

  • CeftazidimeDrug

    1.0 gram IV over 1 hour

  • Piperacillin/tazobactamDrug

    4.5 grams IV over 1 hour

  • AztreonamDrug

    1.0 gram IV over 1 hour

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics: Maximum concentration (Cmax)Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8
  2. Pharmacokinetics: Area under the concentration-time curve from time 0 to last measurable time-point (AUC0-t)Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8
  3. Pharmacokinetics: Area under the concentration-time curve from time 0 to infinity (AUC0-inf)Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8
  4. Pharmacokinetics: Time to maximum concentration (Tmax)Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8
  5. Pharmacokinetics: Terminal Elimination Rate Constant (kel)Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8
  6. Pharmacokinetics: Terminal half-life (t1/2)Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8
  7. Pharmacokinetics: Terminal clearance (CL)Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8
  8. Pharmacokinetics: Volume of distribution (Vd)Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Simbec Research, Ltd.

    Merthyr Tydfil, Mid Glamorgan, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.